On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.
|Articles|June 19, 2020
Osteoporosis Treatment Under COVID-19
A steering committee of the American Society for Bone Mineral Research recently issued COVID-19 treatment guidelines for patients receiving osteoporosis treatments. In this interview, E. Michael Lewiecki, M.D., director of the New Mexico Clinical Research and Osteoporosis Center and a University of New Mexico program called Bone Health TeleECHO, shares his best practices for treating osteoporosis patients during the pandemic.
Advertisement
Advertisement
Related to this article
At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Advertisement
Advertisement